Ironwood Pharmaceuticals said today it will halt development of IW-9179 for diabetic gastroparesis following the failure of a Phase IIa clinical trial in the indication.

Ironwood acknowledged that IW-9179 did not meaningfully reduce the severity of symptoms in diabetic gastroparesis patients compared with placebo: “The data were not what we all hoped for,” the company stated in a Twitter tweet.

Instead, Ironwood said, it will focus on ongoing drug-development programs in three franchises—irritable bowel syndrome with constipation/chronic idiopathic constipation, vascular and fibrotic disease, and refractory gastroesophageal reflux disease.

The Phase IIa study was a randomized, double-blind, placebo-controlled study of oral IW-9179 administered to 90 patients with diabetic gastroparesis. Patients were randomized to receive IW-9179 or placebo once or twice daily for 4 weeks. Ironwood said it assessed efficacy through multiple patient assessments of cardinal symptoms associated with gastroparesis.

Despite the lack of meaningful improvement of symptoms, IW-9179 was generally well tolerated, with the most common adverse event being diarrhea, which Ironwood said was mostly mild to moderate in nature.

The decision comes 2 years after Ironwood terminated a Phase II study of IW-9179 in functional dyspepsia (NCT01712412) before completing enrollment. In a statement at the time, the company cited “challenges with the rigorous enrollment exclusion criteria in the trial,” and added that preliminary data supported continued development. IW-9179 is still listed as being in development for functional dyspepsia on the company’s pipeline website page, last updated February 18.








This site uses Akismet to reduce spam. Learn how your comment data is processed.